" class="no-js "lang="en-US"> FDA Grants Accelerated Approval for Urothelial Cancer Treatment
Saturday, April 20, 2024

FDA Grants Accelerated Approval for PADCEV® with KEYTRUDA for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Seagen and Astellas Pharma have announced the United States Food and Drug Administration (FDA) has granted PADCEV® with KEYTRUDA® (pembrolizumab) accelerated approval in the US as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication is contingent upon verification and description of clinical benefit in the EV-302 confirmatory trial.

“The accelerated approval for the combination of PADCEV and pembrolizumab marks an important milestone for the approximately 8,000 to 9,000 patients in the United States with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy,” said Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas. “This patient population now has an additional treatment option to treat advanced bladder cancer at first diagnosis of metastatic disease.”

“Advanced-stage urothelial cancer is aggressive and associated with devastating outcomes,” said David R. Epstein, Chief Executive Officer, Seagen. “In the EV-103 clinical trial, the use of PADCEV in combination with pembrolizumab resulted in confirmed and durable tumor responses in over two-thirds of patients with advanced bladder cancer. Global enrollment in the confirmatory trial, EV-302, is complete. With this approval, we look forward to providing a new treatment option that helps address a high unmet need for these patients.”

The U.S. Prescribing Information for PADCEV includes a BOXED WARNING for Serious Skin Reactions as well as the following Warnings and Precautions: hyperglycemia, pneumonitis/interstitial lung disease, peripheral neuropathy, ocular disorders, infusion site extravasation, and embryo-fetal toxicity. Please see below for additional Important Safety Information.

The approval is based on objective response rates (ORR) and median duration of response (DOR) in combined Dose Escalation/Cohort A and Cohort K of the phase 1b/2 EV-103 trial (NCT03288545, also known as KEYNOTE-869). In these EV-103 cohorts, patients treated with PADCEV in combination with pembrolizumab (n=121) obtained a 68% confirmed ORR (95% CI: 58.7 to 76.0) per RECIST v1.1 by blinded independent central review (BICR), with 12% of patients experiencing a complete response and 55% of patients experiencing a partial response. The median DOR per BICR for Dose Escalation/Cohort A was 22.1 months (range: 1.0+ to 46.3+) and was not reached (range: 1.2 to 24.1+) for Cohort K.1 The median number of treatment cycles (per 21-day treatment cycle) was nine in Dose Escalation/Cohort A and 11 in Cohort K.2,3

Results from Cohort K were presented in a late-breaking session at the 2022 European Society for Medical Oncology (ESMO) Congress. Additionally, results from Dose Escalation/Cohort A were published in the Journal of Clinical Oncology in August 2022.

The combination therapy was granted Breakthrough Therapy designation by the FDA in February 2020 based on Dose Escalation/Cohort A data. The combination therapy was also granted Priority Review in December 2022. The accelerated approval granted to the combination therapy today is part of the FDA’s Accelerated Approval Program, which allows approval of a medicine based on a surrogate endpoint if the medicine fills an unmet medical need for a serious condition.

The ongoing phase 3 EV-302 trial (NCT04223856, also known as KEYNOTE-A39) evaluating the clinical benefit of PADCEV in combination with pembrolizumab in patients with previously untreated advanced urothelial cancer is intended to serve as the pivotal confirmatory trial for the U.S. accelerated approval. It is also intended to serve as the basis for global registrations. The trial has completed global enrollment, with the China extension of the study currently enrolling patients.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more